Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    October 2017
  1. PSINAKIS F, Katseli A, Koutsandrea C, Frangia K, et al
    Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.
    Anticancer Res. 2017;37:5719-5726.
    PubMed     Text format     Abstract available


  2. HU WP, Kuo KK, Senadi GC, Chang LS, et al
    Photodynamic Therapy Using Indolines-Fused-Triazoles Induces Mitochondrial Apoptosis in Human Non-Melanoma BCC Cells.
    Anticancer Res. 2017;37:5499-5505.
    PubMed     Text format     Abstract available


  3. GARMPIS N, Damaskos C, Garmpi A, Dimitroulis D, et al
    Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Anticancer Res. 2017;37:5355-5362.
    PubMed     Text format     Abstract available


    September 2017
  4. USLU U, Schliep S, Schliep K, Erdmann M, et al
    Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Anticancer Res. 2017;37:5033-5037.
    PubMed     Text format     Abstract available


    August 2017
  5. KIM YJ, Song SY, Kim W, Jeong SY, et al
    Feasibility of Postoperative Radiotherapy Using Conventional Fractionation for Lymph Node Metastasis from Cutaneous Melanoma.
    Anticancer Res. 2017;37:4239-4246.
    PubMed     Text format     Abstract available


    July 2017
  6. USLU U, Schuler G, Breuninger H
    Factors Influencing Disease Progression in Patients with Head and Neck Melanoma.
    Anticancer Res. 2017;37:3811-3816.
    PubMed     Text format     Abstract available


  7. FURUDATE S, Fujimura T, Kambayashi Y, Kakizaki A, et al
    Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Anticancer Res. 2017;37:3461-3471.
    PubMed     Text format     Abstract available


  8. NATH K, Nelson DS, Roman J, Putt ME, et al
    Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
    Anticancer Res. 2017;37:3413-3421.
    PubMed     Text format     Abstract available


  9. TANAKA T, Fujita M, Hasegawa H, Arimoto A, et al
    Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence.
    Anticancer Res. 2017;37:3863-3869.
    PubMed     Text format     Abstract available


    June 2017
  10. USLU U, Erdmann M, Schliep S, Dorrie J, et al
    Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.
    Anticancer Res. 2017;37:3243-3248.
    PubMed     Text format     Abstract available


  11. JANIK ME, Szlezak D, Surman M, Golas A, et al
    Diversified beta-2-adrenergic Receptor Expression and Action in Melanoma Cells.
    Anticancer Res. 2017;37:3025-3033.
    PubMed     Text format     Abstract available


  12. LAUBE F, Glanz D
    Modulation of Melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based Signaling for TFRC Up-regulation in Human Melanoma Cells.
    Anticancer Res. 2017;37:3001-3007.
    PubMed     Text format     Abstract available


    April 2017
  13. YAMAUCHI K, Mitsunaga T, Afroze SH, Uddin MN, et al
    Structure-Activity Relationships of Methylquercetin on Anti-migration and Anti-proliferation Activity in B16 Melanoma Cells.
    Anticancer Res. 2017;37:1575-1579.
    PubMed     Text format     Abstract available


    March 2017

  14. Melanoma Development. Molecular Biology, Genetics and Clinical Application.
    Anticancer Res. 2017;37:1544.
    PubMed     Text format    


  15. YOSHIKAWA S, Kiyohara Y, Otsuka M, Kondou R, et al
    Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Anticancer Res. 2017;37:1321-1328.
    PubMed     Text format     Abstract available


  16. LAWSON BO, Khong HT
    Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
    Anticancer Res. 2017;37:1365-1368.
    PubMed     Text format     Abstract available


  17. SPILIOPOULOS K, Peschos D, Batistatou A, Ntountas I, et al
    Immunohistochemical Study of Vasculogenic Mimicry and Angiogenesis in Melanocytic Tumors of the Eye and the Periocular Area.
    Anticancer Res. 2017;37:1113-1120.
    PubMed     Text format     Abstract available


    February 2017
  18. RYU SH, Heo SH, Park EY, Choi KC, et al
    Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes.
    Anticancer Res. 2017;37:607-614.
    PubMed     Text format     Abstract available


    January 2017
  19. SEHMISCH L, Schild SE, Rades D
    Development of a Survival Score for Patients with Cerebral Metastases from Melanoma.
    Anticancer Res. 2017;37:249-252.
    PubMed     Text format     Abstract available


  20. FORTIS SP, Anastasopoulou EA, Voutsas IF, Baxevanis CN, et al
    Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
    Anticancer Res. 2017;37:143-148.
    PubMed     Text format     Abstract available


  21. NGUYEN AH, Detty SQ, Agrawal DK
    Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Anticancer Res. 2017;37:1-7.
    PubMed     Text format     Abstract available


    December 2016
  22. RADES D, Sehmisch L, Janssen S, Schild SE, et al
    Prognostic Factors After Whole-brain Radiotherapy Alone for Brain Metastases from Malignant Melanoma.
    Anticancer Res. 2016;36:6637-6640.
    PubMed     Text format     Abstract available


  23. NAFFOUJE SA, Naffouje R, Chen J, Salti GI, et al
    Validation and Enhancement of the Clinicopathological Melanoma Nomogram via Incorporation of a Molecular Marker in the Primary Tumor.
    Anticancer Res. 2016;36:6603-6610.
    PubMed     Text format     Abstract available


  24. SOLARI N, Gipponi M, Franco DS, Re F, et al
    Videoscopic Inguinal-iliac-obturator Lymph-node Dissection: New Videoscopic Technique for Regional Lymphadenectomy in Patients with Melanoma.
    Anticancer Res. 2016;36:6579-6583.
    PubMed     Text format     Abstract available


  25. YAN S, Holderness BM, Li Z, Seidel GD, et al
    Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.
    Anticancer Res. 2016;36:6449-6456.
    PubMed     Text format     Abstract available


  26. MANTSO T, Sfakianos AP, Atkinson A, Anestopoulos I, et al
    Development of a Novel Experimental In Vitro Model of Isothiocyanate-induced Apoptosis in Human Malignant Melanoma Cells.
    Anticancer Res. 2016;36:6303-6309.
    PubMed     Text format     Abstract available


    November 2016
  27. MARTON A, Kusz E, Kolozsi C, Tubak V, et al
    Vanillin Analogues o-Vanillin and 2,4,6-Trihydroxybenzaldehyde Inhibit NFkB Activation and Suppress Growth of A375 Human Melanoma.
    Anticancer Res. 2016;36:5743-5750.
    PubMed     Text format     Abstract available


    October 2016
  28. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


    September 2016
  29. BASNET A, Saad N, Benjamin S
    A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab.
    Anticancer Res. 2016;36:4795-8.
    PubMed     Text format     Abstract available


  30. DONIZY P, Biecek P, Halon A, Matkowski R, et al
    BILLCD8 - A Multivariable Survival Model as a Simple and Clinically Useful Prognostic Tool to Identify High-risk Cutaneous Melanoma Patients.
    Anticancer Res. 2016;36:4739-47.
    PubMed     Text format     Abstract available


  31. RAICA M, Jitariu AA, Cimpean AM
    Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma.
    Anticancer Res. 2016;36:4427-35.
    PubMed     Text format     Abstract available


    August 2016

  32. Melanoma.
    Anticancer Res. 2016;36:4377.
    PubMed     Text format    



  33. Genetics of Melanoma.
    Anticancer Res. 2016;36:4374.
    PubMed     Text format    


    July 2016
  34. LUO H, Umebayashi M, Doi K, Morisaki T, et al
    Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
    Anticancer Res. 2016;36:3585-9.
    PubMed     Text format     Abstract available


  35. CALIK J, Pula B, Piotrowska A, Wojnar A, et al
    Prognostic Significance of NOGO-A/B and NOGO-B Receptor Expression in Malignant Melanoma - A Preliminary Study.
    Anticancer Res. 2016;36:3401-7.
    PubMed     Text format     Abstract available


  36. TANG T, Eldabaje R, Yang L
    Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
    Anticancer Res. 2016;36:3229-41.
    PubMed     Text format     Abstract available


  37. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Text format     Abstract available


  38. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Text format     Abstract available


    June 2016
  39. GORKA E, Fabo D, Gezsi A, Czirbesz K, et al
    Distance from Primary Tumor Is the Strongest Predictor for Early Onset of Brain Metastases in Melanoma.
    Anticancer Res. 2016;36:3065-9.
    PubMed     Text format     Abstract available


  40. YAN S, Coffing BN, Li Z, Xie H, et al
    Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
    Anticancer Res. 2016;36:2871-80.
    PubMed     Text format     Abstract available


    May 2016
  41. ORNAT M, Kobierzycki C, Grzegrzolka J, Pula B, et al
    SOX18 Expression in Non-melanoma Skin Cancer.
    Anticancer Res. 2016;36:2379-83.
    PubMed     Text format     Abstract available


  42. ESPELI V, Ruegg E, Hottinger AF, Modarressi A, et al
    Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
    Anticancer Res. 2016;36:2359-64.
    PubMed     Text format     Abstract available


  43. KIM JK, Kang KA, Ryu YS, Piao MJ, et al
    Induction of Endoplasmic Reticulum Stress via Reactive Oxygen Species Mediated by Luteolin in Melanoma Cells.
    Anticancer Res. 2016;36:2281-9.
    PubMed     Text format     Abstract available


    April 2016
  44. WOJCIECHOWSKA-ZDROJOWY M, Szepietowski JC, Matusiak L, Dziegiel P, et al
    Expression of Podoplanin in Non-melanoma Skin Cancers and Actinic Keratosis.
    Anticancer Res. 2016;36:1591-7.
    PubMed     Text format     Abstract available


  45. HINTSALA HR, Jokinen E, Haapasaari KM, Moza M, et al
    Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.
    Anticancer Res. 2016;36:1497-506.
    PubMed     Text format     Abstract available


    January 2016
  46. ADAMS S, Lin J, Brown D, Shriver CD, et al
    Ultraviolet Radiation Exposure and the Incidence of Oral, Pharyngeal and Cervical Cancer and Melanoma: An Analysis of the SEER Data.
    Anticancer Res. 2016;36:233-7.
    PubMed     Text format     Abstract available


    December 2015
  47. DECOSTER L, Vande Broek I, Neyns B, Majois F, et al
    Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
    Anticancer Res. 2015;35:6893-9.
    PubMed     Text format     Abstract available


  48. BARAK V, Leibovici V, Peretz T, Kalichman I, et al
    Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100beta.
    Anticancer Res. 2015;35:6755-60.
    PubMed     Text format     Abstract available


    November 2015
  49. KRAJSOVA I, Arenberger P, Lakomy R, Kubala E, et al
    Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
    Anticancer Res. 2015;35:6303-10.
    PubMed     Text format     Abstract available


  50. HU WP, Hsu CC, Wang YC, Senadi GC, et al
    Bis(phenylidenebenzeneamine)-1-disulfide Derivatives Induce Autophagy in Melanoma Cells Through a Mitochondria-mediated Pathway.
    Anticancer Res. 2015;35:6075-80.
    PubMed     Text format     Abstract available


    October 2015
  51. PAP M, Bator J, Szeberenyi J
    Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus.
    Anticancer Res. 2015;35:5401-6.
    PubMed     Text format     Abstract available


  52. PROVINCIALI M, Pierpaoli E, Bartozzi B, Bernardini G, et al
    Zinc Induces Apoptosis of Human Melanoma Cells, Increasing Reactive Oxygen Species, p53 and FAS Ligand.
    Anticancer Res. 2015;35:5309-16.
    PubMed     Text format     Abstract available


  53. VETVICKA V, Vetvickova J
    Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells.
    Anticancer Res. 2015;35:5287-92.
    PubMed     Text format     Abstract available


    September 2015
  54. HAN SM, Park CW, Ahn JO, Park SC, et al
    Pro-apoptotic and Growth-inhibitory Effect of IFN-beta-Overexpressing Canine Adipose Tissue-derived Mesenchymal Stem Cells Against Melanoma Cells.
    Anticancer Res. 2015;35:4749-56.
    PubMed     Text format     Abstract available


    August 2015
  55. OTSUBO D, Yamashita K, Fujita M, Nishi M, et al
    Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.
    Anticancer Res. 2015;35:4425-31.
    PubMed     Text format     Abstract available


    July 2015
  56. ZHANG L, Agarwal S, Shohet JM, Zage PE, et al
    CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.
    Anticancer Res. 2015;35:3787-92.
    PubMed     Text format     Abstract available


  57. ADINOLFI B, Carpi S, Romanini A, DA Pozzo E, et al
    Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells.
    Anticancer Res. 2015;35:3781-6.
    PubMed     Text format     Abstract available


    June 2015
  58. KUCERA R, Topolcan O, Treskova I, Kinkorova J, et al
    Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics.
    Anticancer Res. 2015;35:3537-41.
    PubMed     Text format     Abstract available


  59. ZHANG L, Xie Q, Shan SJ, Tabor MK, et al
    Reduced Expression of RECK Protein May Help Differentiate Cutaneous Malignant Melanoma from Melanocytic Nevus.
    Anticancer Res. 2015;35:3185-91.
    PubMed     Text format     Abstract available


    May 2015

  60. BRAF Targets in Melanoma. Biological Mechanisms, Resistance, and Drug Delivery.
    Anticancer Res. 2015;35:3113.
    PubMed     Text format    


  61. WOZNIAK M, Sztiller-Sikorska M, Czyz M
    Expression of miRNAs as Important Element of Melanoma Cell Plasticity in Response to Microenvironmental Stimuli.
    Anticancer Res. 2015;35:2747-58.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: